Loading market dashboard
Smith & Nephew plc
SNNHealthcareNYSEGB
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF ♢ Patient Monitoring System, a data-driven pressure injury prevention platform designed to help health care providers tackle the growing burden of hospital-acquired pressure injuries (HAPIs) by strengthening protocols and outcomes. The LEAF System uses a wearable sensor to monitor patient mobility and provide real-time turn status updates, helping to improve workflow efficiency, turn quality, and protocol adherence.1-3
Veeva Systems expands its medtech reach as Smith+Nephew adopts Veeva Quality Cloud to modernize global quality operations and training.
Smith & Nephew plc (SNN) Q1 2026 Sales/Trading Call Transcript
Medical products maker Smith+Nephew posted a 3.1% rise in first-quarter underlying revenue on Wednesday, helped by strong sports medicine and wound management performance, and kept its annual outlook unchanged while announcing a $500 million share buyback.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming European Wound Management Association (EWMA) Conference, Bremen between 6-8 May 2026.
Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
Smith+Nephew's CARTIHEAL implant shows superior 5-year outcomes vs. standard care, with a new CPT code set to boost adoption and expand cartilage repair reach.
Deprince Race and Zollo Inc. increased its position in shares of Smith and Nephew SNATS, Inc. (NYSE: SNN) by 10.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 375,955 shares of the medical equipment provider's stock after
Results from the first-ever randomized control trial for the REGENETEN Implant in partial-thickness rotator cuff repair SmithNephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces compelling new randomized control trial (RCT) data confirming significant outcome improvements for patients with partial-thickness rotator cuff tears treated with the REGENETEN Bioinductive Implant in isolation.
Barrow Hanley Mewhinney and Strauss LLC cut its position in shares of Smith and Nephew SNATS, Inc. (NYSE: SNN) by 30.6% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 580,206 shares of the medical equipment provider's stock after selling 256,112
Smith + Nephew launches ALLEVYN COMPLETE CARE foam dressing for wound management, expanding its Advanced Wound Management portfolio.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, recently announced the launch of ALLEVYN♢ COMPLETE CARE Foam Dressing, featuring proprietary technologies and performance backed by a portfolio of strong scientific data and clinical evidence.
